Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Naphthoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.78 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.78 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.78 |
| ▸ | CDC25B | P30305 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | WDR5 | P61964 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthoic Acid SCHEMBL28337772 | 0.91 | NR4A1 (0.81) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL27514962 | 0.89 | NR4A1 (0.84) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL30401620 | 0.88 | NR4A1 (0.91) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL28110155 | 0.88 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL29352220 | 0.88 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL30233567 | 0.88 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL17258 | 0.88 | NR4A1 (1.00) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL6442333 | 0.86 | NR4A1 (0.88) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL868316 | 0.86 | NR4A1 (0.95) | NR4A1NR4A2NR4A3CDC25BPLK1 | |
| Naphthoic Acid SCHEMBL6912565 | 0.86 | NR4A1 (0.95) | NR4A1NR4A2NR4A3CDC25BPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642846-B2 | Antifungal drugs | GEORGETOWN UNIVERSITY (US) | 2017-05-09 | — | — | US | claimed |
| US-20160038477-A1 | ANTIFUNGAL DRUGS | GEORGETOWN UNIVERSITY (US) | 2016-02-11 | — | — | US | claimed |
| US-20070087446-A1 | Aromatic phosphonium salts and their use as labeling reagents in mass spectrometry analysis | WATERS INVESTMENTS LIMITED (US) | 2007-04-19 | — | — | US | claimed |
| JP-2006523845-A | — | — | 2006-10-19 | — | — | JP | claimed |
| WO-2004092707-A2 | AROMATIC PHOSPHONIUM SALTS AND THEIR USE AS LABELING REAGENTS MASS SPECTROMETRY ANALYSIS | WATERS INVESTMENTS LIMITED (US) | 2004-10-28 | — | — | WO | claimed |
| US-12043602-B2 | Fendiline derivatives | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3645001-B1 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4387728-A1 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | Alexion Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387655-A1 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING COMPLEMENT ALTERNATIVE PATHWAY INHIBITORS | Alexion Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12016834-B2 | Small molecule inhibitors of SLC25A1 | GEORGETOWN UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| WO-1998016505-A1 | SULFONAMIDE INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016504-A2 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016502-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997045419-A1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997043307-A1 | COMPOUNDS INHIBITING THE ASSOCIATION OF THE PDGF RECEPTOR AND PHOSPHATIDYLINOSITOL 3-KINASE AND THEIR USE | WARNER-LAMBERT COMPANY (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997012903-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING THE BINDING OF PROTEINS CONTAINING AN SH2 DOMAIN TO COGNATE PHOSPHORYLATED PROTEINS | WARNER-LAMBERT COMPANY (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043602-B2 | Fendiline derivatives | CYP11B2, CYP3A7, CYP4F2 | MCL1 4704/4885NR4A1 854/4885NR4A2 738/4885 |
| US-20160038477-A1 | ANTIFUNGAL DRUGS | DPM1, ERG28, CYP51A1 | MCL1 856/4885NR4A1 4584/4885NR4A2 4604/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | MCL1 2655/4885NR4A1 3266/4885NR4A2 1935/4885 |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | MCL1 3762/4885NR4A1 4242/4885NR4A2 2734/4885 |
| US-12016834-B2 | Small molecule inhibitors of SLC25A1 | SLC25A3, SLC2A1, SLC2A2 | MCL1 1386/4885NR4A1 4312/4885NR4A2 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.